{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "interpro:IPR026280",
      "entity_text" : "tissue plasminogen activator",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P00747",
      "entity_text" : "plasminogen",
      "features" : [ {
        "modification_type" : "unknown",
        "feature_type" : "modification"
      } ],
      "entity_type" : "gene_or_gene_product"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "One of the most promising therapies for VOD / SOS is defibrotide, which is a polydeoxyribonucleotide adenosine receptor agonist that has been shown to affect endothelial cell function through the release of prostanoids, increase in tissue plasminogen activator (tPA), decrease levels of plasminogen activator inhibitor (PAI-1), inhibit thrombin induced platelet aggregation, and inhibit leukocyte adhesion to endothelial cells [XREF_BIBR, XREF_BIBR].",
  "reading_complete" : "2020-07-28T11:38:14Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T11:32:59Z",
  "trigger" : "increase",
  "evidence" : [ "increase in tissue plasminogen activator (tPA), decrease levels of plasminogen" ],
  "pmc_id" : "7121262",
  "score" : 0
}